Loading...
•
Dec 31, 2024
Regeneron Q4 2024 Earnings Report
Regeneron's financial performance for Q4 2024 showed revenue growth, driven by key products like Dupixent and Libtayo, and the company initiated a quarterly dividend and increased share repurchase capacity.
Key Takeaways
Regeneron reported a 10% increase in revenue for Q4 2024, reaching $3.79 billion. GAAP EPS was $8.06, and non-GAAP EPS was $12.07. The company initiated a quarterly dividend program and increased its share repurchase capacity to approximately $4.5 billion.
Q4 2024 revenues increased by 10% to $3.79 billion compared to Q4 2023.
Dupixent global net sales increased by 15% to $3.70 billion compared to Q4 2023.
Libtayo global net sales increased by 50% to $367 million compared to Q4 2023.
The company initiated a quarterly cash dividend program and increased total share repurchase capacity to approximately $4.5 billion.
Revenue by Segment
Forward Guidance
Regeneron provided financial guidance for 2025, including GAAP and non-GAAP estimates for R&D and SG&A expenses, gross margin on net product sales, COCM, capital expenditures, and effective tax rates.
Positive Outlook
- GAAP R&D is projected between $5.560 billion and $5.795 billion.
- Non-GAAP R&D is projected between $5.000 billion and $5.200 billion.
- GAAP SG&A is projected between $2.910 billion and $3.095 billion.
- Non-GAAP SG&A is projected between $2.550 billion and $2.700 billion.
- GAAP gross margin on net product sales is expected to be between 84% and 85%.
Challenges Ahead
- Non-GAAP gross margin on net product sales is expected to be between 87% and 88%.
- COCM is projected between $1.000 billion and $1.150 billion.
- Capital expenditures are projected between $850 million and $975 million.
- GAAP effective tax rate is projected between 9% and 11%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...